232 related articles for article (PubMed ID: 20926826)
1. Interaction of recombinant myocilin with the matricellular protein SPARC: functional implications.
Aroca-Aguilar JD; Sánchez-Sánchez F; Ghosh S; Fernández-Navarro A; Coca-Prados M; Escribano J
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):179-89. PubMed ID: 20926826
[TBL] [Abstract][Full Text] [Related]
2. Interaction of myocilin with the C-terminal region of hevin.
Li Y; Aroca-Aguilar JD; Ghosh S; Sánchez-Sánchez F; Escribano J; Coca-Prados M
Biochem Biophys Res Commun; 2006 Jan; 339(3):797-804. PubMed ID: 16316624
[TBL] [Abstract][Full Text] [Related]
3. Functional role of proteolytic processing of recombinant myocilin in self-aggregation.
Aroca-Aguilar JD; Martínez-Redondo F; Sánchez-Sánchez F; Coca-Prados M; Escribano J
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):72-8. PubMed ID: 19696176
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the intracellular proteolytic cleavage of myocilin and identification of calpain II as a myocilin-processing protease.
Sánchez-Sánchez F; Martínez-Redondo F; Aroca-Aguilar JD; Coca-Prados M; Escribano J
J Biol Chem; 2007 Sep; 282(38):27810-24. PubMed ID: 17650508
[TBL] [Abstract][Full Text] [Related]
5. Interplay between hevin, SPARC, and MDGAs: Modulators of neurexin-neuroligin transsynaptic bridges.
Fan S; Gangwar SP; Machius M; Rudenko G
Structure; 2021 Jul; 29(7):664-678.e6. PubMed ID: 33535026
[TBL] [Abstract][Full Text] [Related]
6. The glaucoma-associated olfactomedin domain of myocilin is a novel calcium binding protein.
Donegan RK; Hill SE; Turnage KC; Orwig SD; Lieberman RL
J Biol Chem; 2012 Dec; 287(52):43370-7. PubMed ID: 23129764
[TBL] [Abstract][Full Text] [Related]
7. Myocilin mutations causing glaucoma inhibit the intracellular endoproteolytic cleavage of myocilin between amino acids Arg226 and Ile227.
Aroca-Aguilar JD; Sánchez-Sánchez F; Ghosh S; Coca-Prados M; Escribano J
J Biol Chem; 2005 Jun; 280(22):21043-51. PubMed ID: 15795224
[TBL] [Abstract][Full Text] [Related]
8. Bicarbonate-dependent secretion and proteolytic processing of recombinant myocilin.
Aroca-Aguilar JD; Martínez-Redondo F; Martín-Gil A; Pintor J; Coca-Prados M; Escribano J
PLoS One; 2013; 8(1):e54385. PubMed ID: 23342144
[TBL] [Abstract][Full Text] [Related]
9. Amyloid fibril formation by the glaucoma-associated olfactomedin domain of myocilin.
Orwig SD; Perry CW; Kim LY; Turnage KC; Zhang R; Vollrath D; Schmidt-Krey I; Lieberman RL
J Mol Biol; 2012 Aug; 421(2-3):242-55. PubMed ID: 22197377
[TBL] [Abstract][Full Text] [Related]
10. Structure and Misfolding of the Flexible Tripartite Coiled-Coil Domain of Glaucoma-Associated Myocilin.
Hill SE; Nguyen E; Donegan RK; Patterson-Orazem AC; Hazel A; Gumbart JC; Lieberman RL
Structure; 2017 Nov; 25(11):1697-1707.e5. PubMed ID: 29056483
[TBL] [Abstract][Full Text] [Related]
11. Molecular Insights into Myocilin and Its Glaucoma-Causing Misfolded Olfactomedin Domain Variants.
Lieberman RL; Ma MT
Acc Chem Res; 2021 May; 54(9):2205-2215. PubMed ID: 33847483
[TBL] [Abstract][Full Text] [Related]
12. Perfusion with the olfactomedin domain of myocilin does not affect outflow facility.
Goldwich A; Ethier CR; Chan DW; Tamm ER
Invest Ophthalmol Vis Sci; 2003 May; 44(5):1953-61. PubMed ID: 12714629
[TBL] [Abstract][Full Text] [Related]
13. Heterozygous expression of myocilin glaucoma mutants increases secretion of the mutant forms and reduces extracellular processed myocilin.
Aroca-Aguilar JD; Sánchez-Sánchez F; Martínez-Redondo F; Coca-Prados M; Escribano J
Mol Vis; 2008; 14():2097-108. PubMed ID: 19023451
[TBL] [Abstract][Full Text] [Related]
14. Molecular architecture and modifications of full-length myocilin.
Martin MD; Huard DJE; Guerrero-Ferreira RC; Desai IM; Barlow BM; Lieberman RL
Exp Eye Res; 2021 Oct; 211():108729. PubMed ID: 34400147
[TBL] [Abstract][Full Text] [Related]
15. Different Grp94 components interact transiently with the myocilin olfactomedin domain in vitro to enhance or retard its amyloid aggregation.
Huard DJE; Jonke AP; Torres MP; Lieberman RL
Sci Rep; 2019 Sep; 9(1):12769. PubMed ID: 31484937
[TBL] [Abstract][Full Text] [Related]
16. Cellular immunohistochemical localization of the matricellular protein myocilin in the intervertebral disc.
Gruber HE; Ingram JA; Hanley EN
Biotech Histochem; 2006; 81(4-6):119-24. PubMed ID: 17129994
[TBL] [Abstract][Full Text] [Related]
17. Optimedin: a novel olfactomedin-related protein that interacts with myocilin.
Torrado M; Trivedi R; Zinovieva R; Karavanova I; Tomarev SI
Hum Mol Genet; 2002 May; 11(11):1291-301. PubMed ID: 12019210
[TBL] [Abstract][Full Text] [Related]
18. Proteolysis of the matricellular protein hevin by matrix metalloproteinase-3 produces a SPARC-like fragment (SLF) associated with neovasculature in a murine glioma model.
Weaver M; Workman G; Schultz CR; Lemke N; Rempel SA; Sage EH
J Cell Biochem; 2011 Nov; 112(11):3093-102. PubMed ID: 21688302
[TBL] [Abstract][Full Text] [Related]
19. Inefficient processing of an olfactomedin-deficient myocilin mutant: potential physiological relevance to glaucoma.
Caballero M; Borrás T
Biochem Biophys Res Commun; 2001 Apr; 282(3):662-70. PubMed ID: 11401512
[TBL] [Abstract][Full Text] [Related]
20. Hevin/SC1, a matricellular glycoprotein and potential tumor-suppressor of the SPARC/BM-40/Osteonectin family.
Sullivan MM; Sage EH
Int J Biochem Cell Biol; 2004 Jun; 36(6):991-6. PubMed ID: 15094114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
